{"id":681650,"date":"2023-12-18T19:18:01","date_gmt":"2023-12-18T19:18:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=681650"},"modified":"2023-12-18T19:18:01","modified_gmt":"2023-12-18T19:18:01","slug":"behcets-disease-market-is-projected-to-grow-during-the-forecast-period-20232032-estimates-delveinsight-abbvie-eisai-nobel-pharma-ainos-amgen-janssen-roche-novartis-abbott-iitoo-pharma","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/behcets-disease-market-is-projected-to-grow-during-the-forecast-period-20232032-estimates-delveinsight-abbvie-eisai-nobel-pharma-ainos-amgen-janssen-roche-novartis-abbott-iitoo-pharma_681650.html","title":{"rendered":"Behcet’s Disease Market is Projected to Grow During the Forecast Period (2023-2032) – Estimates DelveInsight | AbbVie, Eisai, Nobel Pharma, Ainos, Amgen, Janssen, Roche, Novartis, Abbott, IItoo Pharma"},"content":{"rendered":"
\n
\"Behcet's<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
As per DelveInsight, the Beh\u00e7et’s Disease Market is anticipated to evolve immensely in the coming years owing to the increase in R&D activity, rising prevalent population, and the expected commercial success of the pipeline therapies.<\/div>\n

DelveInsight’s “Behçet’s Disease Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Behçet’s Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The report covers emerging Behçet’s Disease drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Behçet’s Disease treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

Behçet’s Disease: An Overview<\/strong><\/p>\n

Behçet’s syndrome also known as Bycet disease is a rare chronic, relapsing, and debilitating inflammatory multisystem disease of unknown etiology characterized by ulcers affecting the mouth and genitals, various skin lesions, and abnormalities affecting the eyes. Typically, painful canker sores on the mouth’s mucous membranes are Behçet’s syndrome’s first sign (aphthous stomatitis). The eyes may potentially be impacted by Behçet’s syndrome. Inflammation of the anterior chamber and the posterior uveitis are two symptoms that can occur (anterior uveitis or iridocyclitis). It is also possible for the iris to become inflamed and experience pain, tearing, and pus buildup (hypopyon iritis).<\/p>\n

Due to the absence of any pathognomic test findings, Behcet’s must be diagnosed clinically, which can be challenging. Leukocytosis, elevated inflammatory marker levels, and anemia of chronic disease are examples of common, non-specific laboratory results. Imaging studies must focus on the affected organ and may include X-rays, arthrocentesis to evaluate arthritis, CT scans to evaluate for bleeding, thrombosis, and ischemia, angiography to look for aneurysms and lumbar punctures to assess meningitis. Imaging studies must also be directed at the affected organ.<\/p>\n

The goal of treatment is to prevent organ damage. Based on organ involvement, severity, and prognostic variables, the treatment plan is chosen. If severe vascular involvement is unresponsive to medical management, surgical measures may be necessary. Fistulas, intestinal stenosis, perforations, pulmonary artery aneurysms, glaucoma, cataracts, and CNS aneurysms are also treated surgically.<\/p>\n

Behçet’s Disease Market Key Facts<\/strong><\/p>\n